Search Share Prices
Indivior hails court order blocking Dr Reddy's suboxone launch
Indivior has won a temporary restraining order by a US court compelling rival drugmaker Dr Reddy's Labs to immediately stop any launch activities related to its generic version of Suboxone Film.
The US District Court for the District of New Jersey's restraining order will remain in place at least until a hearing on the preliminary injunction motion that Indivior filed on Friday when Dr Reddy's won approval from the US drug regulator to produce a generic version of the sublingual film, which is used as a treatment for opioid addiction.
Dr Reddy's announced the approval from US Food & Drug Administration and said it would launch the buprenorphine and naloxone film.
This statement to launch was despite Indivior having recently filed litigation against Dr Reddy's and others related to the '305 patent.
On Monday, Indivior said it aimed to use the district court hearing, for which a preliminary injunction motion has been scheduled for 28 June, to seek to stop Dr Reddy's from launching its generic film pending the outcome of that litigation.
Chief executive Shaun Thaxter said: "We are pleased that the court has granted our request for a temporary restraining order. This order will stop Dr Reddy's launch activities before the court has had a chance to rule on the preliminary injunction motion. We will continue to pursue all legal avenues against Dr Reddy's to protect our Suboxone Film patent estate."